First-Line Inhaler for COPD

Initial Treatment Based on Symptom Burden

The American Thoracic Society recommends long-acting bronchodilator maintenance therapy for all symptomatic individuals with COPD, including those with mild symptoms 1
Short-acting bronchodilators should be available as rescue therapy for all patients, as recommended by the American Journal of Respiratory and Critical Care Medicine 2, 3
Patients must be taught proper inhaler technique before prescribing, as 76% make critical errors with metered-dose inhalers, according to Thorax 4

The American College of Chest Physicians strongly recommends LAMA/LABA dual therapy over monotherapy for patients with moderate to severe dyspnea or significantly reduced health status 1
Single inhaled LAMA/LABA dual therapy is recommended for moderate and severe disease, as stated by the American College of Chest Physicians 1
Triple therapy with LAMA/LABA/ICS in a single inhaler is first-line for high exacerbation risk patients, according to the American College of Chest Physicians 6, 1
Triple therapy significantly reduces mortality compared to LAMA/LABA dual therapy in high-risk patients with FEV1 <80% predicted, as reported by the American College of Chest Physicians 6

Inhaled corticosteroid monotherapy is not recommended and should not be used, as stated by the American College of Chest Physicians 7
Short-acting bronchodilators alone are insufficient for maintenance therapy in symptomatic patients, according to the American College of Chest Physicians 1
Nebulized therapy should not be first-line, as recommended by the European Respiratory Society 8, 9

Confirm COPD diagnosis with spirometry and assess symptom burden, as recommended by the American College of Chest Physicians 6, 1
For all symptomatic patients, prescribe as-needed short-acting bronchodilator, according to the American Journal of Respiratory and Critical Care Medicine 2, 3
Stratify patients by exacerbation risk and start LAMA or LABA monotherapy for mild symptoms, escalating to LAMA/LABA dual therapy for moderate-severe symptoms, as stated by the American College of Chest Physicians 1
For high-risk patients, start LAMA/LABA/ICS triple therapy in a single inhaler, as recommended by the American College of Chest Physicians 6, 1